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OPEN
EDITORIAL
Blood vessels and cancer much more than just angiogenesis
Cell Death Discovery (2015) 1, 15064; doi:10.1038/cddiscovery.2015.64;
published online 21 December 2015
The availability of oxygen and nutrients supplied by the
vasculature is crucial for both normal and neoplastic
cells, however, the nature of the intratumour vessels and
their relationship to the neoplastic cells has been debated for
centuries.
The introduction of the concept of angiogenesis in tumours, i.e.
formation of new vessels, goes back as far as 17871 and in 1939
Ide et al.2 described that tumour implants in the ears of rabbits
were accompanied by formation of new capillaries leading to the
idea that angiogenesis is necessary to support tumours. Yet, at the
same time several histopathologists maintained the point that
both pre-existing and newly formed vessels were co-existing in
tumours and, sometime, only pre-existing vessels could be
observed.3 However, it was not until 30 years later that the
subject started to be systematically studied by Judah Folkman4
following the path indicated by Ide.
Folkman’s pioneering work on cancer and its relationship to
vessels lead him and many others to describe the response of
tumours to hypoxia as leading to angiogenesis, and therefore
allowing cancer growth.5 The biological pathways underlying
these processes were assumed to be pretty much common to all
the tumours leading to the concept of ‘Inducing angiogenesis’ as
an Hallmark of Cancer.6 On this assumption it was also deduced
that by targeting the tumour-associated newly formed vessels, the
cancer cells deprived of their newly formed vascular bed would
die or, at least, would stop growing and would become dormant.7
However, an increasing body of evidence, initially from
histopathological studies and subsequently from animal models
and clinical trials, has uncovered an added layer of complexity: the
possibility that some primary and metastatic tumours can develop
and progress in the absence of angiogenesis, by exploiting the
pre-existing vasculature.8 Surprisingly, tumours growing in this
way have been described in the past (Figure 1), but then
forgotten.
The discovery that, alongside purely nonangiogenic tumors,
there is a large number of cases containing both pre-existing
vessels and newly formed ones,9 shows that ‘inducing angio-
genesis’ is not an essential Hallmark of Cancer and lack of
angiogenesis is far from being an exception.
This observation has also raised the question of the relative
importance of angiogenesis versus pre-existing vessels in the high
proportion of cancers containing both: therefore, in a large number
of tumours, we can not be sure of how much angiogenesis and
how much pre-existing vessels are contributing to tumour growth.
These ﬁndings are therefore seriously questioning the idea that
Folkman’s postulates are still largely valid.10
The best characterization so far of this type of growth is in
malignant lesions of lung, liver and brain cancer. The non-angiogenic
growth implies that as these tumours grow without the pathways of
classical angiogenesis, they must have a different biological setting,
so a new chapter in cancer biology is now in front of us. Among the
new questions now raised, there are four main ones.
First, as these tumours, either primary or metastatic, grow and
experience hypoxia why is angiogenesis not triggered?11,12 It is
likely that this is speciﬁc to their biology than failure to respond to
hypoxia. Attempts to map the pathways underlying the biological
behaviour of such tumours suggest that metabolic reprogram-
ming with a switch towards oxidative phosphorylation, under the
control of selected heat-shock proteins, oncogenes and tumour-
suppressor genes, could be one of the key issues.11,13
The second key question is how the cancer cells interact with
and co-opt the vessels and how this process varies in different
organs. Only a few studies, most focused on the brain, have so far
addressed this issue. In primary brain carcinoma, cells are directed
towards the vessels by the bradykinin signalling pathways,14
whereas metastatic cells instead accumulate around the vessels
after extravasation and they are protected from apoptosis by
neuroserpin.15 Adhesion of the malignant cells to the vessels can
be mediated by L1CAM,15 beta1 integrin16 and/or connexins
establishing gap junctions.17 In some of these models, the co-
opted vessels eventually regress, following overexpression of
angiopoietin 2 and ultimately angiogenesis is triggered.18,19
Some early data are also emerging to support co-option in the
lung. In a recent study,20 Szabo et al. for the ﬁrst time investigated
in mouse models the anatomical interaction between cancer cells
and the lung vessels during co-option. By employing confocal and
electron microscopy the authors show that the metastatic cells
ﬁrst accumulate, after extravasation, within the alveolar wall to
subsequently enter the airspace. Once there the metastases
expand, as the malignant cells spread from one alveolar space to
another as previously described.3 When the metastasis expands,
some carcinoma cells appear to re-enter the alveolar wall
positioning themselves between the endothelium and the
epithelium. In this location, the metastatic cells split the basal
membrane and anchor themselves to both the endothelial and
the epithelial side. This is in broad agreement with the observed
capacity that malignant cells have in the brain to anchor
themselves to the basal membrane by L1CAM15 or beta1
integrin.16 The epithelial cells eventually detach from their basal
membrane and undergo fragmentation. There is a different
picture in the liver where the cancer cells exploit the liver blood
ﬂow by replacing the hepatocytes,21 but how this happens
remains so far unclear.
Figure 1. Nonangiogenic lung metastases described as ‘Intra-
alveolar spread of a metastatic carcinoma of bladder in lung’ in
1948 ‘Pathology of Tumours’ by Rupert Willis.23
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Third, the canonical angiogenesis pathway hypothesized
that neoplastic cells switch early on to angiogenic status
and than cancer progression follows.7 Nevertheless, in contrast
to this theory, non angiogenic metastases can occur in patients
with angiogenic primary tumours.22 Whether this is owing to
selection of nonangiogenic clones or possibility for a cell to
switch back to a non-angiogenic setting, remains to be
established.
Fourth, as some ﬁrst studies on metastases show that co-option
can be associated with inhibition of apoptosis,15 the question
arises on how apoptosis and vascular co-option are related. Is this
critical to the establishment of metastases, even independently of
the subsequent vascular arrangements?
Clinically, the ability to identify vascular co-option in cancer is
relevant to treatment for two main reasons: ﬁrst is that it may be
one of the causes of resistance to antiangiogenic drugs, and the
identiﬁcation of vascular co-option will help to distinguish which
tumours are more likely to beneﬁt and improve trial design. The
second reason is that by unveiling the pathways dictating the
nonangiogenic growth of cancer cells new targets for treatment
could be discovered.
We are therefore once again spectators of what Thomas Huxley
called ‘The great tragedy of science—the slaying of a beautiful
hypothesis by an ugly fact.’
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